Yi Zhang and shareholders representing over 59.2% of the outstanding shares of YS Biopharma Co., Ltd. (company or YS) announced the successful approval of all resolutions at the YS Extraordinary General Meeting of Shareholders (EGM) held on February 16, 2024. Immediately following the successful conclusion of the EGM, the new board of directors of the Company voted [unanimously] to effect the following resolutions (among others): the removal of Chunyuan (Brenda) Wu from all positions with the Company and any subsidiaries of the Company, including without limitation as chief financial officer of the Company; the appointment Hongman Jia as the chief financial officer of the Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.96 USD | -1.83% | +6.65% | +87.87% |
04-19 | YS Biopharma Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2023 | CI |
04-18 | YS Biopharma Receives Clinical Trial Approval for Potential Hepatitis B Treatment | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+87.87% | 184M | |
-3.05% | 90.45B | |
+3.95% | 41.45B | |
-10.51% | 33.57B | |
+60.58% | 25.73B | |
-20.09% | 14.73B | |
-8.92% | 12.82B | |
-11.46% | 11.7B | |
-43.05% | 11.44B | |
+5.17% | 8.79B |
- Stock Market
- Equities
- YS Stock
- News YS Biopharma Co., Ltd.
- YS Biopharma Co., Ltd. Announces Chief Financial Officer Changes